Immunic's (IMUX) Buy Rating Reaffirmed at Brookline Capital Management

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Brookline Capital Management in a report issued on Friday, MarketBeat reports. They presently have a $10.00 target price on the stock.

Separately, StockNews.com downgraded shares of Immunic from a "hold" rating to a "sell" rating in a report on Friday, March 29th.

Immunic Price Performance

IMUX stock opened at $1.29 on Friday. The firm has a fifty day moving average price of $1.31 and a two-hundred day moving average price of $1.27. The firm has a market cap of $116.01 million, a price-to-earnings ratio of -0.61 and a beta of 2.07. Immunic has a 1-year low of $0.95 and a 1-year high of $3.11.

Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.03. As a group, analysts expect that Immunic will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunic

Several institutional investors have recently bought and sold shares of IMUX. LPL Financial LLC acquired a new stake in Immunic in the 2nd quarter valued at about $28,000. American Century Companies Inc. acquired a new stake in Immunic in the 3rd quarter valued at about $31,000. JPMorgan Chase & Co. lifted its holdings in Immunic by 1,143.9% in the 4th quarter. JPMorgan Chase & Co. now owns 24,903 shares of the company's stock valued at $35,000 after acquiring an additional 22,901 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in Immunic in the 2nd quarter valued at about $36,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Immunic in the 1st quarter valued at about $37,000. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.